PIRS Projected Dividend Yield
Pieris Pharmaceuticals Inc ( NASDAQ : PIRS )Pieris Pharmaceuticals is a biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. Co.'s clinical pipeline includes elarekibep an inhaled IL-4Ra antagonist Anticalin protein to treat uncontrolled asthma, PRS-220, an inhaled CTGF antagonist to treat IPF and other forms for fibrotic lung disease, an immuno-oncology (IO) bispecific PRS-344/S095012 targeting PD-L1 and 4-1BB. Co. has intellectual property rights directed to various aspects of its Anticalin technology platform, allowing for the development and improvement of both its platform and drug candidates. Co.'s development plans focus on its clinical and preclinical programs. 21 YEAR PERFORMANCE RESULTS |
PIRS Dividend History Detail PIRS Dividend News PIRS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |